ondansetron has been researched along with Carcinoma, Squamous Cell in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domínguez-Ortega, L | 1 |
| Cubedo-Cervera, R | 1 |
| Cortés-Funés, H | 1 |
| Díaz-Gállego, E | 1 |
1 trial available for ondansetron and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Sleep protects against chemotherapy induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; | 1996 |